Sign in
CompletedPhase 3

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women

Key facts

Who runs it
Sinovac Biotech Co., Ltd
Where
Philippines2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
150 people enrolled
Started
13 Oct 2025
Ended
26 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV
  • Vaxigrip QIV
Record updated
10 November 2026

Who can take part

Age
18 years to 39 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Pregnant women aged 18 to 39 years in good health or medically stable
  • Gestational age of 20 to 32 weeks, based on last menstrual period, early or late ultrasound dating
  • The participant was tested negative for HIV, Syphilis, Hepatitis B, Hepatitis C infection according to medical records or rapid tests
  • Participants should provide verifiable identification
  • Participants are able to understand and sign the informed consent form voluntarily
  • Participants are willing and able to adhere to visit schedules and all study requirements

Who cannot take part

  • Receipt of any seasonal influenza vaccine within 6 months prior to enrollment, or plans to receive other influenza vaccines during the study
  • Participants with previous or concurrent dangerous pregnancy complications such as gestational diabetes mellitus (GDM), pregnant induced hypertension, preeclampsia and known uterine anomaly
  • History of Guillain-Barré syndrome within 6 weeks of a prior dose of any influenza vaccine
  • Received any vaccine in the 4 weeks prior to study vaccination, or plans to receive any vaccine within 4 weeks after study vaccination
  • Autoimmune diseases, immunodeficiency, any immunosuppressant within 6 months prior to vaccination (≥ 20mg/day prednisone or equivalent, but corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis are permitted) or cytotoxic therapy, or plans for such treatment during the study
  • Acute diseases or acute stage of chronic diseases within 7 days prior to vaccination
  • Receipt of blood, blood-derived products or immunoglobulins within 3 months prior to vaccination or plans for such treatment in the study
  • Receipt of other investigational drugs/vaccines within 30 days prior to enrollment, or plan to receive investigational drugs/vaccines during the study period
  • History of preterm delivery, or spontaneous abortion
  • Serious allergic reaction or other serious adverse reaction to any influenza vaccines or their components
  • Significant chronic diseases that, in the judgement of the investigator, might interfere with the study (may include, but are not limited to cardiovascular disease, liver or kidney disorders, HIV infection or malignant tumor)
  • Current or history of severe neurological diseases (such as epilepsy, convulsions or seizures) or psychiatric disorders, or family history of psychiatric disorders
  • Alcoholism or history of drug abuse
  • Diagnosed abnormal coagulation function (e.g., coagulation factor deficiency, coagulation disorders, or platelet abnormalities), or obvious bruising following venipuncture
  • Known fetal congenital anomaly, e.g. genetic abnormality or major congenital malformation based on antenatal ultrasound
  • Signs or symptoms of active preterm labor, defined as regular uterine contractions with cervical change (dilation/effacement)
  • Fever on vaccination day, with axillary temperature ≥ 37.3°C pre-vaccination
  • Any other factors which are unsuitable for participation in the clinical trial as judged by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blind, positive controlled phase Ⅲ clinical trial to assess the immunogenicity and safety of Sinovac QIV in pregnant women. A total of 150 healthy pregnant women aged 18~39 years at 20 to 32 weeks of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac QIV or Vaxigrip QIV, respectively.

Read full original descriptionShow less

Blood samples will be collected from participants prior to vaccination and 28 days after vaccination. Moreover, to evaluate trans-placental antibodies, blood samples at the end of the gestation period (delivery) and the cord blood sample will be collected, if applicable.

For safety assessment, any immediate adverse events within 30 minutes, solicited local and systemic adverse events within 7 days and unsolicited adverse events within 28 days will be collected. Serious adverse events will be collected within 8 weeks after delivery. Pregnancy and birth outcomes will be collected as well.

The 2 groups in the trial

  • Test GroupTreatment being tested

    Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Treatment: Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

  • Control GroupExisting treatment, for comparison

    Participants will receive one dose of vaccine (0.5 mL) of Vaxigrip QIV

    Treatment: Vaxigrip QIV

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ⅲ, Randomized, Double-blind, Positive Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of an Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
Record updated
10 November 2026